Free Trial

AbbVie (ABBV) Stock Price, News & Analysis

$188.57
-1.89 (-0.99%)
(As of 10/17/2024 ET)

About AbbVie Stock (NYSE:ABBV)

Key Stats

Today's Range
$188.46
$191.62
50-Day Range
$188.57
$199.35
52-Week Range
$135.85
$199.95
Volume
4.31 million shs
Average Volume
5.30 million shs
Market Capitalization
$332.99 billion
P/E Ratio
62.86
Dividend Yield
3.29%
Price Target
$198.00
Consensus Rating
Moderate Buy

Company Overview

AbbVie Inc. is a US-based biopharma company with global operations. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock.

Over the years, AbbView Inc. has made numerous acquisitions. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Botox accounts for the bulk of the company’s Aesthetics portfolio revenue and about 4% of the net as of 2022. The total revenue in 2021 was $56.20 billion with a 31% operating margin.

Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community.

The company’s original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions.

The company is focused on research and has a number of collaborations and partnerships to that end. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each.

As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. The company’s operations span 20 countries, treating more than 60 million people and 40 conditions annually.

AbbVie has 5 focus areas for its research and products. These are Immunology, Oncology, Neurology, Virology and Eye Care. The company has a robust pipeline of new products that are in some stage of clinical trials. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions.

AbbVie is a leader in ESG and sustainability. The company is a member of the Fortune 100 and one of the Fortune 100’s “Best Companies To Work For”. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most.

AbbVie Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
99th Percentile Overall Score

ABBV MarketRank™: 

AbbVie scored higher than 99% of companies evaluated by MarketBeat, and ranked 21st out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 13 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    AbbVie has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about AbbVie's stock forecast and price target.
  • Earnings Growth

    Earnings for AbbVie are expected to grow by 11.61% in the coming year, from $10.85 to $12.11 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AbbVie is 62.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.51.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AbbVie is 62.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 138.69.

  • Price to Earnings Growth Ratio

    AbbVie has a PEG Ratio of 2.66. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    AbbVie has a P/B Ratio of 32.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about AbbVie's valuation and earnings.
  • Percentage of Shares Shorted

    0.84% of the float of AbbVie has been sold short.
  • Short Interest Ratio / Days to Cover

    AbbVie has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AbbVie has recently decreased by 16.47%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    AbbVie pays a meaningful dividend of 3.19%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    AbbVie has been increasing its dividend for 52 years.

  • Dividend Coverage

    The dividend payout ratio of AbbVie is 183.98%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, AbbVie will have a dividend payout ratio of 51.20% next year. This indicates that AbbVie will be able to sustain or increase its dividend.

  • Read more about AbbVie's dividend.
  • Percentage of Shares Shorted

    0.84% of the float of AbbVie has been sold short.
  • Short Interest Ratio / Days to Cover

    AbbVie has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AbbVie has recently decreased by 16.47%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    AbbVie has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 29 news articles for AbbVie this week, compared to 25 articles on an average week.
  • Search Interest

    138 people have searched for ABBV on MarketBeat in the last 30 days. This is an increase of 34% compared to the previous 30 days.
  • MarketBeat Follows

    Only 44 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $61,901,455.00 in company stock.

  • Percentage Held by Insiders

    Only 0.25% of the stock of AbbVie is held by insiders.

  • Percentage Held by Institutions

    70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about AbbVie's insider trading history.
Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Stock News Headlines

Full frame shot of composed various medical supplies on blue surface — Photo
Best Pharma Stocks for Long-Term Investors: Growth and Dividends
Big pharmaceutical firms may lack the potential for rally driven by a breakout drug like small biotechs, but stability and steady growth remain attractive.
KONSKIE, POLAND - AUGUST 18, 2018: AbbVie logo displayed on a modern smartphone - Stock Editorial Photography
AbbVie Stock Eyes New Highs: Analysts See Strong Growth Potential
AbbVie is tracking for a new high that may be reached before the end of the year. Acquisitions fuel the growth outlook, cash flow and capital returns.
War on Elon Escalates…
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
See More Headlines

ABBV Stock Analysis - Frequently Asked Questions

AbbVie's stock was trading at $154.97 at the start of the year. Since then, ABBV shares have increased by 21.7% and is now trading at $188.57.
View the best growth stocks for 2024 here
.

AbbVie Inc. (NYSE:ABBV) released its quarterly earnings data on Thursday, July, 25th. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.08. The business's revenue for the quarter was up 4.3% compared to the same quarter last year.
Read the conference call transcript
.

AbbVie subsidiaries include Mavupharma, Allergan, Stem CentRx, Pharmacyclics Inc, ImmuVen, AbbVie AB, AbbVie AG, and others.

AbbVie's top institutional shareholders include Swedbank AB (0.12%), Guinness Asset Management LTD (0.07%), Handelsbanken Fonder AB (0.06%) and Creative Planning (0.04%). Insiders that own company stock include Richard A Gonzalez, Azita Saleki-Gerhardt, Michael Severino, Robert A Michael, Jeffrey Ryan Stewart, Nicholas Donoghoe, Roxanne S Austin, Carrie C Strom, Elaine K Sorg, Scott T Reents, Henry O Gosebruch, Timothy J Richmond, Perry C Siatis, Kevin K Buckbee, Brian L Durkin and Laura J Schumacher.
View institutional ownership trends
.

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that AbbVie investors own include NVIDIA (NVDA), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), Chevron (CVX), Vanguard Short-Term Inflation-Protected Securities ETF (VTIP), Salesforce (CRM) and Intact Financial (IFC).

Company Calendar

Ex-Dividend for 8/15 Dividend
7/15/2024
Last Earnings
7/25/2024
Dividend Payable
8/15/2024
Ex-Dividend for 11/15 Dividend
10/15/2024
Today
10/17/2024
Next Earnings (Confirmed)
10/30/2024
Dividend Payable
11/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
00287Y10
Employees
50,000
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$198.69
High Stock Price Target
$225.00
Low Stock Price Target
$150.00
Potential Upside/Downside
+5.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.94
Research Coverage
17 Analysts

Profitability

Net Income
$4.86 billion
Pretax Margin
12.85%

Debt

Sales & Book Value

Annual Sales
$55 billion
Cash Flow
$15.32 per share
Book Value
$5.78 per share

Miscellaneous

Outstanding Shares
1,765,868,000
Free Float
1,761,928,000
Market Cap
$332.99 billion
Optionable
Optionable
Beta
0.63

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (NYSE:ABBV) was last updated on 10/17/2024 by MarketBeat.com Staff
From Our Partners